ELAHERE 5 mg/mL
MIRVETUXIMAB SORAVTANSINE · INJECTION, SOLUTION · ImmunoGen, Inc.
Elahere is an intravenous injection used to treat certain types of ovarian cancer in patients whose tumors express a specific protein called folate receptor alpha. It works by delivering a cancer-fighting agent directly to cancer cells that have this protein.
Key Facts
- Brand Name
- ELAHERE
- Generic Name
- MIRVETUXIMAB SORAVTANSINE
- NDC Code (Product)
72903-853- Manufacturer
- ImmunoGen, Inc.
- Strength
- 5 mg/mL
- Dosage Form
- INJECTION, SOLUTION
- Route
- INTRAVENOUS
- Marketing Status
- Application #
- BLA761310
- Marketing Start
- 11/14/2022
Recall History
No Recall HistoryFrequently Asked Questions
What is ELAHERE used for?
Elahere is an intravenous injection used to treat certain types of ovarian cancer in patients whose tumors express a specific protein called folate receptor alpha. It works by delivering a cancer-fighting agent directly to cancer cells that have this protein.
Is ELAHERE a controlled substance?
ELAHERE is not classified as a controlled substance by the DEA.
What is the generic name for ELAHERE?
The generic name for ELAHERE is MIRVETUXIMAB SORAVTANSINE. There are no other listed brand versions of MIRVETUXIMAB SORAVTANSINE.
What is the NDC code for ELAHERE 5 mg/mL?
The NDC (National Drug Code) for ELAHERE 5 mg/mL is 72903-853, listed by ImmunoGen, Inc..
Not medical advice. Always consult your doctor or pharmacist before making any medication decisions.
Data from openFDA · Public domain (CC0 1.0)